{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:34:14Z","timestamp":1768293254607,"version":"3.49.0"},"reference-count":23,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cerebrovasc Dis"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Despite improvements in treatment, stroke still carries a high death toll and disability in Asia. Extended-release dipyridamole (ER-DP) plus acetylsalicylic acid (ASA) has consistently been shown to be superior over conventional platelet inhibition by ASA. ER-DP plus ASA is well established in the secondary prevention of stroke in a lot of countries including the USA and Europe. DP has an established benefit in the treatment of heart disease in Japan; however, for the prevention of stroke, the fixed-dose combination of ER-DP plus ASA has only been investigated in a small number of patients in Japan. &lt;i&gt;Methods:&lt;\/i&gt; The aim of this double-blind, randomized clinical trial was to investigate the efficacy and safety of ER-DP plus ASA versus 81 mg ASA over 1 year. The primary end point of this study was the event rate of recurrent ischemic stroke (fatal or nonfatal) using the Kaplan-Meier method and Cox regression analysis. &lt;i&gt;Results:&lt;\/i&gt; Of the 1,294 enrolled patients, the primary end point was analyzed in 652 patients in the ER-DP plus ASA group and 639 in the ASA group. The incidence of ischemic stroke was 6.9% for ER-DP plus ASA and 5.0% for ASA with a hazard ratio of 1.47 (95% confidence interval 0.93\u20132.31) for the primary end point. The ASA treatment group was found to have a lower than expected yearly event rate, compared to other studies in Japanese stroke patients. Noninferiority of ER-DP plus ASA versus ASA could not be shown. The risks of major bleeding events and intracranial hemorrhage were found to be similar between the treatment arms. There were 4 deaths (0.6%) in the ER-DP plus ASA group and 10 (1.6%) in the ASA group. &lt;i&gt;Conclusions:&lt;\/i&gt; The results of the study are inconclusive. Noninferiority of ER-DP plus ASA versus ASA could not be established, a difference between treatments could not be shown for the primary end point. Possible reasons for this result include a small sample size, low event rates and too short a treatment duration (ClinicalTrials. gov number, NCT00311402).<\/jats:p>","DOI":"10.1159\/000327035","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T10:36:45Z","timestamp":1303209405000},"page":"601-613","source":"Crossref","is-referenced-by-count":36,"title":["The Japanese Aggrenox (Extended-Release Dipyridamole plus Aspirin) Stroke Prevention versus Aspirin Programme (JASAP) Study: A Randomized, Double-Blind, Controlled Trial"],"prefix":"10.1159","volume":"31","author":[{"given":"Shinichiro","family":"Uchiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Urano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Horie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,4,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161%2FCIRCULATIONAHA.108.790048"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161%2FSTROKEAHA.110.581363"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159%2F000083252"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1747-4949.2009.00272.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161%2F01.STR.0000090348.52943.A2"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2FS0022-510X%2896%2900308-5"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2806%2968734-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161%2FSTROKEAHA.107.189063"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000131083"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161%2FSTROKEAHA.107.505131"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS1474-4422%2810%2970198-8"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0805002"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2FS1474-4422%2809%2970361-8"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000314624"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa061894"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2810%2960309-1"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016%2FS0140-6736%2810%2960308-X"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016%2FS1474-4422%2810%2970066-1"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11883-008-0008-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1536%2Fjhj.45.977"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161%2FATVBAHA.107.160226"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093%2Fcvr%2Fcvq002"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161%2F01.CIR.0000154607.90506.45"}],"container-title":["Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/327035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/327035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:10:04Z","timestamp":1745435404000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000327035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,5,1]]},"published-print":{"date-parts":[[2011,5,5]]}},"URL":"https:\/\/doi.org\/10.1159\/000327035","archive":["Portico"],"relation":{},"ISSN":["1015-9770","1421-9786"],"issn-type":[{"value":"1015-9770","type":"print"},{"value":"1421-9786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}